MACF1
Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5
Also known as: ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA0754, KIAA1251, Lnc-PMIF, MACF, MACF1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UPN3
- Gene
- MACF1
- Ensembl
- ENSG00000127603
- Chromosome
- 1
- Canonical length
- 7388 aa
- Protein class
- Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Subcellular location
- Plasma membrane,Cell Junctions,Actin filaments,Basal body
OverviewNCBI Gene
This gene encodes a large protein containing numerous spectrin and leucine-rich repeat (LRR) domains. The encoded protein is a member of a family of proteins that form bridges between different cytoskeletal elements. This protein facilitates actin-microtubule interactions at the cell periphery and couples the microtubule network to cellular junctions. Alternative splicing results in multiple transcript variants, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, May 2013]
Canonical amino-acid sequenceUniProt
7388 residues, UniProt reviewed canonical sequence.
>Q9UPN3|MACF1
1 MSSSDEETLS ERSCRSERSC RSERSYRSER SGSLSPCPPG DTLPWNLPLH EQKKRKSQDS
61 VLDPAERAVV RVADERDRVQ KKTFTKWVNK HLMKVRKHIN DLYEDLRDGH NLISLLEVLS
121 GIKLPREKGR MRFHRLQNVQ IALDFLKQRQ VKLVNIRNDD ITDGNPKLTL GLIWTIILHF
181 QISDIYISGE SGDMSAKEKL LLWTQKVTAG YTGIKCTNFS SCWSDGKMFN ALIHRYRPDL
241 VDMERVQIQS NRENLEQAFE VAERLGVTRL LDAEDVDVPS PDEKSVITYV SSIYDAFPKV
301 PEGGEGISAT EVDSRWQEYQ SRVDSLIPWI KQHTILMSDK TFPQNPVELK ALYNQYIHFK
361 ETEILAKERE KGRIEELYKL LEVWIEFGRI KLPQGYHPND VEEEWGKLII EMLEREKSLR
421 PAVERLELLL QIANKIQNGA LNCEEKLTLA KNTLQADAAH LESGQPVQCE SDVIMYIQEC
481 EGLIRQLQVD LQILRDENYY QLEELAFRVM RLQDELVTLR LECTNLYRKG HFTSLELVPP
541 STLTTTHLKA EPLTKATHSS STSWFRKPMT RAELVAISSS EDEGNLRFVY ELLSWVEEMQ
601 MKLERAEWGN DLPSVELQLE TQQHIHTSVE ELGSSVKEAR LYEGKMSQNF HTSYAETLGK
661 LETQYCKLKE TSSFRMRHLQ SLHKFVSRAT AELIWLNEKE EEELAYDWSD NNSNISAKRN
721 YFSELTMELE EKQDVFRSLQ DTAELLSLEN HPAKQTVEAY SAAVQSQLQW MKQLCLCVEQ
781 HVKENTAYFQ FFSDARELES FLRNLQDSIK RKYSCDHNTS LSRLEDLLQD SMDEKEQLIQ
841 SKSSVASLVG RSKTIVQLKP RSPDHVLKNT ISVKAVCDYR QIEITICKND ECVLEDNSQR
901 TKWKVISPTG NEAMVPSVCF LIPPPNKDAI EMASRVEQSY QKVMALWHQL HVNTKSLISW
961 NYLRKDLDLV QTWNLEKLRS SAPGECHQIM KNLQAHYEDF LQDSRDSVLF SVADRLRLEE
1021 EVEACKARFQ HLMKSMENED KEETVAKMYI SELKNIRLRL EEYEQRVVKR IQSLASSRTD
1081 RDAWQDNALR IAEQEHTQED LQQLRSDLDA VSMKCDSFLH QSPSSSSVPT LRSELNLLVE
1141 KMDHVYGLST VYLNKLKTVD VIVRSIQDAE LLVKGYEIKL SQEEVVLADL SALEAHWSTL
1201 RHWLSDVKDK NSVFSVLDEE IAKAKVVAEQ MSRLTPERNL DLERYQEKGS QLQERWHRVI
1261 AQLEIRQSEL ESIQEVLGDY RACHGTLIKW IEETTAQQEM MKPGQAEDSR VLSEQLSQQT
1321 ALFAEIERNQ TKLDQCQKFS QQYSTIVKDY ELQLMTYKAF VESQQKSPGK RRRMLSSSDA
1381 ITQEFMDLRT RYTALVTLTT QHVKYISDAL RRLEEEEKVV EEEKQEHVEK VKELLGWVST
1441 LARNTQGKAT SSETKESTDI EKAILEQQVL SEELTTKKEQ VSEAIKTSQI FLAKHGHKLS
1501 EKEKKQISEQ LNALNKAYHD LCDGSANQLQ QLQSQLAHQT EQKECRAVAG VIDLGTVEIF
1561 PIFKAMQKGL LDQDTGLVLL ESQVIMSGLI APETGENLSL EEGIARNLIN PQMYQQLREL
1621 QDALALISRL TESRGPLSVV EAIEKRIISE TVGLKILEAH LATGGFSLSP SENCINLEEA
1681 FHQGLISAWL HSVLESYLRT SKNLIDPNTA EKIGLLDLMQ RCIVHQESGF KLLPVKQLAG
1741 GMVSLKSGRK VSIFRAVQEG LIDRQVTVRL LEAQLFAGGI VDPRTGHRLT VEEAVRHNLI
1801 DQDMACAILI RQLQTGGIID TVTGQRLTID EAVSNDLVAA KIALVILESL WSFMGLLWPE
1861 SGEILPITDA LEQGIVSTEL AHKILSNRQH IKALFLPATT EILSWKKAIE SGILDRDLAN
1921 NLKSICIPDV MPHMQLADSA EQNINPGAAV LPCSKSHPKA TASQSENLLF QLMTHSYINV
1981 QNGQRLLLLD KELMETLTSR DEYQTSPPKV VEIGHQRQKT PEGLQESANV KISGTFSSGW
2041 TVRLPEFQFS SQNKEYPDRE DCTTEKGKKT TVETEDSSVE NPEQDLFVEQ KERNPNIDAL
2101 KVINKVKLEV QRQLIGTQRE DQTAVSVREN ASRGHLLTIP PAEAEGVPLV VDKDVFSVET
2161 PKKEHQPLRN TSFTCQNEQA HTLETEYIHD ETGGSHIKPQ SKKLQVQVKK TLGIKLELKS
2221 ETDGNVHPLD KKEMLKKTFL AKDDHKESQE AQNIAGGSMM MSEKTDEEDS GREIFLSCSH
2281 PLELLEEATL NVLSAQLLDG GIFHEQTGQK LLLNEAISRG IVPSHTAVKL MEKLNMFQGF
2341 FDSQTCESLT TEEVINEGLM DEKLLHNVLM ADKAISGVLD PRTQTLCSVK DAVTVGLLDK
2401 ETATRILERQ VVTGGIIDLK RGKKVSVTLA STLGLVDVAD QPELINLEKA SKGRDAEKTV
2461 RERLISLQME TTGLIDPDSK APLTVVQSID RGLLEREEAV RLLTKQVVDG GIIHHISGMR
2521 LSVDNAFRHG LIGEDLAEKL KRVENLNIHQ IFNPETKENI SLPKAIKLDL ITSDLKREIQ
2581 EVQAFTGNFV DLISGQRLTL AEAKKEGLLT NEAVLSPGMM HGIVDPENCR IVPYSELVKK
2641 CKIDIESGQR YLEVIPFSDI KDGVSDKVLT LSQAIQLGKV DFASTLKVLE AQANTGGIID
2701 TATGKRLTLA SALEEKLVDE NMVRIIASHQ VLNGGIVDIF SDQRVTLVEA IEKRLISPEL
2761 ANMIQIDSSE FSDHRAQIEK QEGIEVCALQ NEFLGKDMLI ACNQTAEMSC NKVEESERLF
2821 QVENQSAQEK VKVRVSDGEQ AKKSREISLK EFGCKDQRKP RMSSDAKEFI SIINPHNLKG
2881 KSLGQVSLTH PYSECDFKLK EVARNNMGND TNEEQEKAVT KIEIISHMKQ STSCLDSEEI
2941 RENQGEVILE VQETYCETSG KLPSEQVLQQ PMNARVKSKR EKREVIVEES IRTCKPAFLS
3001 EEKLYQETAI RDEHDSHIKS QPREMTSSEK GKEADTEMGF SITFKIEESS SQVVPQGISV
3061 KHLDALTLFS SKQANEGKVN NLSLCLTLKP EENLSREIAC GAQSEPFPCM TPRPEGLHYQ
3121 ESDGKAQVTG PSQISKTDKS FQGTTRQETN YQDSWVTSKT KETKHQISSS NECKEKSYQE
3181 VSFDPARGLK LEEITVSRPD SKEVRYLEFS DRKDLHHQGS KSDDKLCGTL KSEIATQELT
3241 GEKFLEMANP NVAGLEAGSI EDIVTQRGSR VLGSFLPEKL FKGVSQKENT GQQNAIISPT
3301 VLETSEEKTV SLTVCSAVKT EKTPQEKLRE SPGSEQTPFM TAPEGKGNGG VNPEPFRATQ
3361 NVFTRQLCLE HDEKLVSYLS LLRNIEMRTK QIQPLELNLA ELQDLLCQAK VLERELKDLT
3421 TLVSQELECV NQIIISQPQE VPAQLLKALE KDAKNLQKSL SSVSDTWNSR LLHFQNAVEI
3481 EKTKVLNQHT QLEGRLQDLR AWVGNKNLIL NSKGSNSEID VDSLNLCLQQ YEDLKQPMAE
3541 RKAQLDALAF DIQFFISEHA QDLSPQQNRQ MLRLLNELQR SFQDILEQTA AQVDALQGHL
3601 QQMEQEALVK TLQKQQNTCH QQLEDLCSWV GQAERALAGH QGRTTQQDLS ALQKNQSDLK
3661 DLQDDIQNRA TSFATVVKDI EGFMEENQTK LSPRELTALR EKLHQAKEQY EALQEETRVA
3721 QKELEEAVTS ALQQETEKSK AAKELAENKK KIDALLDWVT SVGSSGGQLL TNLPGMEQLS
3781 GASLEKGALD TTDGYMGVNQ APEKLDKQCE MMKARHQELL SQQQNFILAT QSAQAFLDQH
3841 GHNLTPEEQQ MLQQKLGELK EQYSTSLAQS EAELKQVQTL QDELQKFLQD HKEFESWLER
3901 SEKELENMHK GGSSPETLPS LLKRQGSFSE DVISHKGDLR FVTISGQKVL DMENSFKEGK
3961 EPSEIGNLVK DKLKDATERY TALHSKCTRL GSHLNMLLGQ YHQFQNSADS LQAWMQACEA
4021 NVEKLLSDTV ASDPGVLQEQ LATTKQLQEE LAEHQVPVEK LQKVARDIME IEGEPAPDHR
4081 HVQETTDSIL SHFQSLSYSL AERSSLLQKA IAQSQSVQES LESLLQSIGE VEQNLEGKQV
4141 SSLSSGVIQE ALATNMKLKQ DIARQKSSLE ATREMVTRFM ETADSTTAAV LQGKLAEVSQ
4201 RFEQLCLQQQ EKESSLKKLL PQAEMFEHLS GKLQQFMENK SRMLASGNQP DQDITHFFQQ
4261 IQELNLEMED QQENLDTLEH LVTELSSCGF ALDLCQHQDR VQNLRKDFTE LQKTVKEREK
4321 DASSCQEQLD EFRKLVRTFQ KWLKETEGSI PPTETSMSAK ELEKQIEHLK SLLDDWASKG
4381 TLVEEINCKG TSLENLIMEI TAPDSQGKTG SILPSVGSSV GSVNGYHTCK DLTEIQCDMS
4441 DVNLKYEKLG GVLHERQESL QAILNRMEEV HKEANSVLQW LESKEEVLKS MDAMSSPTKT
4501 ETVKAQAESN KAFLAELEQN SPKIQKVKEA LAGLLVTYPN SQEAENWKKI QEELNSRWER
4561 ATEVTVARQR QLEESASHLA CFQAAESQLR PWLMEKELMM GVLGPLSIDP NMLNAQKQQV
4621 QFMLKEFEAR RQQHEQLNEA AQGILTGPGD VSLSTSQVQK ELQSINQKWV ELTDKLNSRS
4681 SQIDQAIVKS TQYQELLQDL SEKVRAVGQR LSVQSAISTQ PEAVKQQLEE TSEIRSDLEQ
4741 LDHEVKEAQT LCDELSVLIG EQYLKDELKK RLETVALPLQ GLEDLAADRI NRLQAALAST
4801 QQFQQMFDEL RTWLDDKQSQ QAKNCPISAK LERLQSQLQE NEEFQKSLNQ HSGSYEVIVA
4861 EGESLLLSVP PGEEKRTLQN QLVELKNHWE ELSKKTADRQ SRLKDCMQKA QKYQWHVEDL
4921 VPWIEDCKAK MSELRVTLDP VQLESSLLRS KAMLNEVEKR RSLLEILNSA ADILINSSEA
4981 DEDGIRDEKA GINQNMDAVT EELQAKTGSL EEMTQRLREF QESFKNIEKK VEGAKHQLEI
5041 FDALGSQACS NKNLEKLRAQ QEVLQALEPQ VDYLRNFTQG LVEDAPDGSD ASQLLHQAEV
5101 AQQEFLEVKQ RVNSGCVMME NKLEGIGQFH CRVREMFSQL ADLDDELDGM GAIGRDTDSL
5161 QSQIEDVRLF LNKIHVLKLD IEASEAECRH MLEEEGTLDL LGLKRELEAL NKQCGKLTER
5221 GKARQEQLEL TLGRVEDFYR KLKGLNDATT AAEEAEALQW VVGTEVEIIN QQLADFKMFQ
5281 KEQVDPLQMK LQQVNGLGQG LIQSAGKDCD VQGLEHDMEE INARWNTLNK KVAQRIAQLQ
5341 EALLHCGKFQ DALEPLLSWL ADTEELIANQ KPPSAEYKVV KAQIQEQKLL QRLLDDRKAT
5401 VDMLQAEGGR IAQSAELADR EKITGQLESL ESRWTELLSK AAARQKQLED ILVLAKQFHE
5461 TAEPISDFLS VTEKKLANSE PVGTQTAKIQ QQIIRHKALN EEIVNRKKNV DQAIKNGQAL
5521 LKQTTGEEVL LIQEKLDGIK TRYADITVTS SKALRTLEQA RQLATKFQST YEELTGWLRE
5581 VEEELATSGG QSPTGEQIPQ FQQRQKELKK EVMEHRLVLD TVNEVSRALL ELVPWRAREG
5641 LDKLVSDANE QYKLVSDTIG QRVDEIDAAI QRSQQYEQAA DAELAWVAET KRKLMALGPI
5701 RLEQDQTTAQ LQVQKAFSID IIRHKDSMDE LFSHRSEIFG TCGEEQKTVL QEKTESLIQQ
5761 YEAISLLNSE RYARLERAQV LVNQFWETYE ELSPWIEETR ALIAQLPSPA IDHEQLRQQQ
5821 EEMRQLRESI AEHKPHIDKL LKIGPQLKEL NPEEGEMVEE KYQKAENMYA QIKEEVRQRA
5881 LALDEAVSQS TQITEFHDKI EPMLETLENL SSRLRMPPLI PAEVDKIREC ISDNKSATVE
5941 LEKLQPSFEA LKRRGEELIG RSQGADKDLA AKEIQDKLDQ MVFFWEDIKA RAEEREIKFL
6001 DVLELAEKFW YDMAALLTTI KDTQDIVHDL ESPGIDPSII KQQVEAAETI KEETDGLHEE
6061 LEFIRILGAD LIFACGETEK PEVRKSIDEM NNAWENLNKT WKERLEKLED AMQAAVQYQD
6121 TLQAMFDWLD NTVIKLCTMP PVGTDLNTVK DQLNEMKEFK VEVYQQQIEM EKLNHQGELM
6181 LKKATDETDR DIIREPLTEL KHLWENLGEK IAHRQHKLEG ALLALGQFQH ALEELMSWLT
6241 HTEELLDAQR PISGDPKVIE VELAKHHVLK NDVLAHQATV ETVNKAGNEL LESSAGDDAS
6301 SLRSRLEAMN QCWESVLQKT EEREQQLQST LQQAQGFHSE IEDFLLELTR MESQLSASKP
6361 TGGLPETARE QLDTHMELYS QLKAKEETYN QLLDKGRLML LSRDDSGSGS KTEQSVALLE
6421 QKWHVVSSKM EERKSKLEEA LNLATEFQNS LQEFINWLTL AEQSLNIASP PSLILNTVLS
6481 QIEEHKVFAN EVNAHRDQII ELDQTGNQLK FLSQKQDVVL IKNLLVSVQS RWEKVVQRSI
6541 ERGRSLDDAR KRAKQFHEAW KKLIDWLEDA ESHLDSELEI SNDPDKIKLQ LSKHKEFQKT
6601 LGGKQPVYDT TIRTGRALKE KTLLPEDSQK LDNFLGEVRD KWDTVCGKSV ERQHKLEEAL
6661 LFSGQFMDAL QALVDWLYKV EPQLAEDQPV HGDLDLVMNL MDAHKVFQKE LGKRTGTVQV
6721 LKRSGRELIE NSRDDTTWVK GQLQELSTRW DTVCKLSVSK QSRLEQALKQ AEVFRDTVHM
6781 LLEWLSEAEQ TLRFRGALPD DTEALQSLID THKEFMKKVE EKRVDVNSAV AMGEVILAVC
6841 HPDCITTIKH WITIIRARFE EVLTWAKQHQ QRLETALSEL VANAELLEEL LAWIQWAETT
6901 LIQRDQEPIP QNIDRVKALI AEHQTFMEEM TRKQPDVDRV TKTYKRKNIE PTHAPFIEKS
6961 RSGGRKSLSQ PTPPPMPILS QSEAKNPRIN QLSARWQQVW LLALERQRKL NDALDRLEEL
7021 KEFANFDFDV WRKKYMRWMN HKKSRVMDFF RRIDKDQDGK ITRQEFIDGI LASKFPTTKL
7081 EMTAVADIFD RDGDGYIDYY EFVAALHPNK DAYRPTTDAD KIEDEVTRQV AQCKCAKRFQ
7141 VEQIGENKYR FGDSQQLRLV RILRSTVMVR VGGGWMALDE FLVKNDPCRA RGRTNIELRE
7201 KFILPEGASQ GMTPFRSRGR RSKPSSRAAS PTRSSSSASQ SNHSCTSMPS SPATPASGTK
7261 VIPSSGSKLK RPTPTFHSSR TSLAGDTSNS SSPASTGAKT NRADPKKSAS RPGSRAGSRA
7321 GSRASSRRGS DASDFDLLET QSACSDTSES SAAGGQGNSR RGLNKPSKIP TMSKKTTTAS
7381 PRTPGPKRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MACF1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0
- Highest tissue expression
- 94 nTPM
Expression across tissuesHPA
Tissue
- colon: 94 nTPM
- midbrain: 90 nTPM
- basal ganglia: 88 nTPM
- parathyroid gland: 86 nTPM
- amygdala: 85 nTPM
- heart muscle: 84 nTPM
Single-cell type
- ocular epithelial cells: 2,163 nCPM
- astrocytes: 1,735 nCPM
- podocytes: 1,415 nCPM
- basal keratinocytes: 1,164 nCPM
- suprabasal keratinocytes: 1,159 nCPM
- cone photoreceptor cells: 1,132 nCPM
Immune cell
- gdT-cell: 7.6 nTPM
- memory CD8 T-cell: 6 nTPM
- basophil: 5.9 nTPM
- NK-cell: 5 nTPM
- naive CD8 T-cell: 3.8 nTPM
- memory CD4 T-cell: 3.4 nTPM
Brain region
- basal ganglia: 295 nTPM
- medulla oblongata: 289 nTPM
- thalamus: 285 nTPM
- pons: 266 nTPM
- midbrain: 265 nTPM
- white matter: 254 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MACF1.
Disease | AllUniProt
Conditions MACF1 is implicated in, by any mechanism.
- Lissencephaly 9 with complex brainstem malformation (LIS9) MIM:618325
Disease | GeneticClinVar
22 pathogenic / likely-pathogenic of 2,040 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Lissencephaly 9 with complex brainstem malformation
- Lissencephaly with decussation defect
- lissencephaly with brainstem hypoplasia
- Lissencephaly
- Short stature
Disease | ImmuneIEDB
Conditions an epitope on MACF1 was assayed in.
- type 1 diabetes mellitus T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.08
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.43
- DepMap mean gene effect
- -0.13
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- Golgi to plasma membrane protein transport
- intermediate filament cytoskeleton organization
- positive regulation of axon extension
- positive regulation of Wnt signaling pathway
- regulation of cell migration
- regulation of epithelial cell migration
- regulation of focal adhesion assembly
- regulation of microtubule-based process
- regulation of neuron projection arborization
- Wnt signaling pathway
- wound healing
Molecular functions
- actin binding
- actin filament binding
- cadherin binding
- calcium ion binding
- microtubule minus-end binding
- RNA binding
- structural molecule activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Plectin repeat
- SH3 domain
- Actinin-type actin-binding domain, conserved site
- Calponin homology domain
- Spectrin repeat
- EF-hand domain
- GAR domain
- EF-hand domain pair
- Spectrin/alpha-actinin
- EF-Hand 1, calcium-binding site
- Plakin repeat superfamily
- GAR domain superfamily
- CH domain superfamily
- Desmoplakin, spectrin-like domain
- Desmoplakin, SH3 domain
- Plakin
- Plectin-like, spectrin-like repeat
- Calponin homology (CH) domain
- Spectrin repeat
- Plectin repeat
- Growth-Arrest-Specific Protein 2 Domain
- EF-hand domain pair
- SH3 domain
- Spectrin like domain
- Spectrin-like repeat
- Spectrin-like repeat
- Spectrin repeat
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MACF1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MACF1 as an antibody target. Whether an autoantibody or antibody against MACF1 could matter depends on whether native MACF1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MACF1 is annotated at the cell surface, where native MACF1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label MACF1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...